Azelis: H1 2026 Results: Return to Organic Growth
Azelis H1 2026: €2.2bn revenue (+3.2%), organic growth returned to +0.3% after four-quarter decline via pricing gains and acquisition growth. Specialty chemicals stabilization reduces cost uncertainty in semiconductor and AI infrastructure supply chains.
Azelis: H1 2026 Results: Return to Organic Growth
Regulatory News:
Azelis Group NV (Brussels:AZE):
Highlights H1 2026
Revenue of EUR 2.2bn, representing a 3.2% increase in constant currency, reflecting organic growth of 0.3% and a 2.9% growth contribution from acquisitions. In Q2, revenue increased by 6.3% in constant currency to EUR 1.1bn, driven by a return to organic growth (+3.9% year-on-year) following four quarters of decline, as well as a 2.4% growth contribution from acquisitions.
Melexis retrouve de l’élan et bat les attentes au deuxième trimestre
ASM International posts EUR 1.003B in Q2 revenue, beating analyst expectations
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales
Gli Stati Uniti e l’estero trainano il semestre di Galderma (+24,6%) | MilanoFinanza News
Les bourses en direct | Azelis et Solvay bondissent en tête du Bel 20, Elia et Melexis en panne, BMW vise 8.000 licenciements
L"Oréal corre a +5,8%, volano margini e utile | MilanoFinanza News
Legrand: 2026 First-Half Results
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises…
Verallia: 2026 First Half Results: Higher Cash Generation, 2026 Outlook Confirmed
Havas Reports Solid H1 2026 Results With Organic Growth of +2.5% and Further Improvement in Adjusted EBIT Margin
Balance Sheet Restructuring Combined with Revenue Growth Drives Approximately 73% Improvement in Revenue per Dollar of Year-End…
ARKEMA: SECOND-QUARTER 2026 RESULTS
